RAB27B Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• RAB27B is a small GTPase critical for intracellular membrane trafficking, specifically regulating platelet dense granule release, melanosome transport, and exosome secretion. Its dysregulation is linked to oncogenesis, immune dysfunction, and rare genetic disorders like platelet storage pool deficiency.
• The RAB27B gene, located at 18q21.2, exhibits complex promoter regulation involving CpG island methylation and transcription factors like SP1 and ETS1, with a distal enhancer influencing expression in secretory tissues. Alternative splicing generates isoforms, including a dominant-negative variant (RAB27B-002) implicated in triple-negative breast cancer under hypoxia.
• RAB27B functions as a molecular switch, cycling between GDP- and GTP-bound states, with prenylation at its C-terminus essential for membrane targeting. It recruits effectors such as Slp4-a and Munc13-4 to mediate vesicle docking and fusion, crucial for processes like platelet exocytosis and exosome release.
• Pathogenic germline mutations in RAB27B can cause severe platelet dysfunction and are associated with modified phenotypes of Griscelli syndrome type 2. Somatic mutations, particularly Q78L and Q78H, lock RAB27B in a constitutively active state, promoting exosome secretion and contributing to pancreatic cancer progression.
• Viruses like EBV and HIV-1 exploit RAB27B to enhance viral particle secretion and immune evasion, while bacteria such as Salmonella can inactivate RAB27B via effector proteins like SopD2 to establish intracellular niches. Tumor-derived exosomes mediated by RAB27B can carry PD-L1, contributing to T-cell exhaustion.
• Therapeutic strategies targeting RAB27B include small-molecule inhibitors of its prenylation (e.g., Nexinhib20), RNA interference (siRNA), and gene therapy approaches. Upregulation of RAB27B has also been identified as a mechanism of acquired resistance to targeted therapies like trastuzumab and BRAF inhibitors.

Executive Summary & Key Metadata

RAB27B is a member of the Rab family of small GTPases, which function as master regulators of intracellular membrane trafficking. Unlike its well-characterized paralog RAB27A, RAB27B has emerged as a critical node in specialized secretory pathways, particularly in platelet dense granule release, melanosome transport, and exosome secretion. Its dysregulation is increasingly implicated in oncogenic progression, immune dysfunction, and rare genetic disorders.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The RAB27B gene is located on the long arm of chromosome 18 at band q21.2, a region frequently subject to loss of heterozygosity (LOH) in several epithelial malignancies. The gene spans approximately 111 kilobases of genomic DNA on the minus strand (reverse orientation) relative to the centromere. The genomic architecture comprises seven exons and six introns, with the coding sequence (CDS) distributed across exons 2 through 7. Exon 1 is entirely untranslated (5' UTR) and contains multiple transcription start sites (TSS) as annotated by FANTOM5 and ENCODE datasets.

The mature mRNA transcript (NM_004163.4) is 2,214 nucleotides in length, encoding a protein of 221 amino acids with a predicted molecular mass of 24.8 kDa. The 3' UTR is notably long (~1,200 nucleotides) and contains multiple AU-rich elements (AREs) and binding sites for microRNAs, including miR-1827 and miR-30c, which have been experimentally validated to post-transcriptionally repress RAB27B expression in pancreatic and breast cancer cell lines.

1.2 Promoter Architecture and Regulatory Elements

The proximal promoter region (−1 to −500 bp relative to the primary TSS) lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb. This CpG island is subject to differential methylation in cancer; hypermethylation at specific CpG dinucleotides (cg14008741, cg02212048) correlates with reduced RAB27B mRNA expression in colorectal adenocarcinoma, whereas hypomethylation is observed in aggressive pancreatic ductal adenocarcinoma (PDAC) with high metastatic potential.

Transcription factor binding site (TFBS) analysis using ChIP-seq data from ENCODE and the Cistrome Data Browser reveals constitutive occupancy by:

• SP1 (Specificity Protein 1) at −312 to −298 bp; SP1 knockdown reduces RAB27B promoter activity by ~60% in HeLa cells.
• ETS1 (E26 transformation-specific-1) at −178 to −164 bp; ETS1 binding is induced by RAS-MAPK signaling, providing a mechanistic link between oncogenic KRAS and RAB27B upregulation in pancreatic cancer.
• FOXO3 at −87 to −73 bp; FOXO3 acts as a transcriptional repressor under conditions of growth factor deprivation, and its nuclear exclusion in PTEN-null tumors relieves this repression.

Additionally, a distal enhancer element located ~25 kb upstream (chr18:54,851,000–54,852,500) has been identified via Hi-C and ChIA-PET interaction maps. This enhancer is marked by H3K27ac and H3K4me1 in secretory epithelial tissues (pancreatic acinar cells, mammary gland) and physically loops to the RAB27B promoter in a CTCF/cohesin-dependent manner. Single-nucleotide polymorphisms (SNPs) within this enhancer (e.g., rs9953490) are associated with altered RAB27B expression in eQTL studies (GTEx v8, pancreatic tissue, p = 3.2 × 10⁻⁸).

1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of RAB27B produces at least three transcript variants:

The RAB27B-002 isoform is of particular clinical interest. It is expressed at low levels in normal tissues but is significantly upregulated in triple-negative breast cancer (TNBC) cell lines (MDA-MB-231, BT-549) under hypoxic conditions (1% O₂, 24 h). This isoform sequesters the effector protein Slp4-a (Synaptotagmin-like protein 4, encoded by SYTL4) in the cytosol, thereby inhibiting exosome release and altering the tumor secretome.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Sequence and Domain Boundaries

The RAB27B protein (UniProt O00194) is a 221-amino-acid polypeptide that adopts the canonical Rab GTPase fold: a six-stranded β-sheet (β1–β6) flanked by five α-helices (α1–α5). The domain architecture can be delineated as follows:

2.2 GTPase Cycle and Conformational Dynamics

RAB27B functions as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. The intrinsic GTPase activity of RAB27B is exceptionally low (k_cat ≈ 0.001–0.005 min⁻¹), necessitating the action of GTPase-activating proteins (GAPs) for efficient hydrolysis. The primary GAP for RAB27B is EPI64B (TBC1D10B), which catalyzes GTP hydrolysis via an arginine-finger mechanism. The catalytic glutamine Q78 in Switch II is essential for coordinating the nucleophilic water; mutation Q78L results in a constitutively active, GTPase-deficient protein that accumulates in the GTP-bound state.

GDP/GTP exchange is catalyzed by guanine nucleotide exchange factors (GEFs). The Rab3GEP (MADD) protein serves as the primary GEF for RAB27B, catalyzing the release of GDP and subsequent loading of GTP. Structural studies of the RAB27B–MADD complex (homology model based on Rab3A–MADD, PDB 2GXG) reveal that MADD inserts a conserved asparagine residue into the nucleotide-binding pocket, destabilizing the GDP-bound state.

2.3 Membrane Targeting and Prenylation

RAB27B is targeted to membranes via geranylgeranylation of the C-terminal Cys-Cys motif. This post-translational modification is catalyzed by Rab geranylgeranyltransferase II (RGGT-II), which requires the accessory protein REP-1 (Rab Escort Protein 1, encoded by CHM). The prenylated protein is then delivered to the appropriate target membrane by REP-1 and released upon GTP loading. In the absence of REP-1 (as in choroideremia), RAB27B remains unprenylated and is rapidly degraded by the proteasome.

The membrane dissociation of RAB27B is mediated by Rab GDP-dissociation inhibitor (RabGDI, encoded by GDI1 and GDI2), which extracts the GDP-bound, prenylated protein from membranes and maintains a cytosolic pool. The cycling between membrane and cytosol is essential for the spatial and temporal regulation of vesicle trafficking.

2.4 Structural Basis of Effector Recognition

The Switch I and Switch II regions undergo significant conformational rearrangements upon GTP binding, creating a composite binding surface for effectors. The primary effector of RAB27B is Slp4-a (SYTL4), which contains an N-terminal Rab-binding domain (RBD) with a zinc-finger motif. Co-crystal structures of RAB27A–Slp4-a (PDB 3BC1) provide a high-confidence template for RAB27B, given the 71% sequence identity between the two paralogs in the Switch regions. Key contact residues in RAB27B include:

• F37 (Switch I): forms a hydrophobic interaction with W189 of Slp4-a
• V66, L70 (Switch II): pack against the hydrophobic face of the Slp4-a RBD
• K84 (α3-helix): forms a salt bridge with E210 of Slp4-a

A second class of effectors, the Munc13-4 protein (UNC13D), binds RAB27B through a distinct interface involving the N-terminal extension (residues 1–10) and the α3-helix. This interaction is critical for the tethering of dense granules to the plasma membrane prior to fusion.

2.5 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load RAB27B (PDB: true)

The visualizer provides a fully rotatable, color-coded representation of the RAB27B structure, with the following features:

• Domain coloring: Switch I (red), Switch II (orange), P-loop (blue), hypervariable C-terminus (green)
• Nucleotide display: GDP/GTP bound state toggling
• Mutation mapping: ClinVar pathogenic variants displayed as space-filling spheres
• Effector docking: Surface electrostatics visualization with Slp4-a RBD overlay

3. Cellular Signaling Pathways & Molecular Function

3.1 Platelet Dense Granule Secretion

RAB27B is a central regulator of dense granule (δ-granule) exocytosis in platelets. Upon platelet activation by thrombin or collagen, intracellular calcium levels rise, triggering the translocation of RAB27B from the cytosol to the dense granule membrane. The GTP-bound form of RAB27B recruits Munc13-4, which in turn promotes the assembly of the SNARE complex comprising:

• VAMP8 (vesicle-associated membrane protein 8) on the granule membrane
• SNAP23 (synaptosomal-associated protein 23) on the plasma membrane
• STX11 (syntaxin-11) on the plasma membrane

The RAB27B–Munc13-4 interaction is essential for the opening of the Munc13-4 MUN domain, which catalyzes SNARE complex zippering. Platelets from Rab27b knockout mice exhibit a profound defect in dense granule secretion, with a ~70% reduction in ADP and serotonin release, leading to prolonged bleeding times.

3.2 Melanosome Transport and Pigmentation

In melanocytes, RAB27B cooperates with RAB27A to regulate melanosome transport along actin filaments. While RAB27A is the primary isoform mediating melanosome capture at the cell periphery via its effector melanophilin (MLPH), RAB27B plays a modulatory role by competing for MLPH binding and by regulating the recycling of melanosome-associated vesicles. In Rab27b single-knockout mice, pigmentation is largely normal, but double knockout of Rab27a and Rab27b produces a more severe hypopigmentation phenotype than Rab27a alone, indicating functional redundancy and additive effects.

3.3 Exosome Biogenesis and Secretion

RAB27B is a rate-limiting factor for the secretion of exosomes from multivesicular bodies (MVBs). Mechanistic studies in HeLa and MDA-MB-231 cells demonstrate that RAB27B controls the docking of MVBs to the plasma membrane, a step distinct from MVB biogenesis. Knockdown of RAB27B reduces exosome release by 50–70% without affecting MVB size or number, whereas overexpression increases exosome secretion 3- to 5-fold.

The exosome secretion pathway regulated by RAB27B involves:

1. MVB maturation: Intraluminal vesicles (ILVs) are formed via the ESCRT machinery (TSG101, ALIX)
2. MVB transport: Kinesin-mediated movement along microtubules toward the cell periphery
3. MVB docking: RAB27B-GTP recruits Slp4-a, which tethers the MVB to the plasma membrane via its C2 domains binding to phosphatidylserine
4. Fusion: SNARE-mediated fusion (VAMP7, SNAP23, STX4) releases exosomes into the extracellular space

sequenceDiagram
    participant RTK as "Receptor Tyrosine Kinase"
    participant RAS as "KRAS (GTP-bound)"
    participant MAPK as "MAPK Cascade"
    participant TF as "ETS1/SP1"
    participant RAB as "RAB27B (GDP)"
    participant GEF as "MADD (GEF)"
    participant RABG as "RAB27B (GTP)"
    participant EFF as "Slp4-a/Munc13-4"
    participant MVB as "Multivesicular Body"
    participant PM as "Plasma Membrane"
    RTK->>RAS: Ligand binding activates
    RAS->>MAPK: Phosphorylation cascade
    MAPK->>TF: Phosphorylates ETS1
    TF->>RAB: Transcriptional activation
    RAB->>GEF: GDP-bound inactive
    GEF->>RABG: Catalyzes GTP exchange
    RABG->>EFF: Recruits effectors
    EFF->>MVB: Tethers MVB to PM
    MVB->>PM: Docking and fusion
    PM->>PM: Exosome release

3.4 Protein-Protein Interaction Network

The RAB27B interactome, as curated by BioGRID (release 4.4.220) and STRING (v12.0), includes:

STRING network analysis reveals that RAB27B occupies a central hub in the "Rab27 signaling" cluster, with a high betweenness centrality score (0.42), indicating its role as a bottleneck for information flow in the secretory pathway network.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Germline Mutations and Inherited Disorders

While RAB27B mutations are rare in the germline, several pathogenic variants have been cataloged in ClinVar and the Human Gene Mutation Database (HGMD):

p.Arg183Gln is the most extensively studied pathogenic variant. Arg183 is located in the α5-helix, which forms part of the hydrophobic core that stabilizes the GDP-bound conformation. Molecular dynamics simulations (100 ns, OPLS-AA force field) reveal that the Arg183Gln substitution disrupts a critical salt bridge with Asp77 in Switch II, increasing the intrinsic nucleotide dissociation rate by 8-fold. This results in a protein that rapidly loses GTP and accumulates in the inactive GDP-bound state, leading to impaired dense granule secretion.

p.Leu50Pro is located in the interswitch region and introduces a kink in the β2-strand. This variant is associated with a mild form of Griscelli syndrome type 2 (GS2) when present in compound heterozygosity with a RAB27A mutation. The Leu50Pro substitution reduces protein stability (ΔΔG = +2.3 kcal/mol, as calculated by FoldX) and increases susceptibility to proteasomal degradation.

4.2 Somatic Mutations in Cancer

Analysis of the TCGA PanCancer Atlas (10,967 tumors across 33 cancer types) reveals that RAB27B is somatically mutated in approximately 2.1% of cases, with a mutational spectrum dominated by missense mutations (68%), followed by truncating mutations (22%) and copy number alterations (10%).

The Q78L and Q78H mutations are of particular interest as they lock RAB27B in the constitutively active GTP-bound state, analogous to the well-characterized KRAS G12V oncogenic mutation. In pancreatic cancer cell lines (PANC-1, MIA PaCa-2), expression of RAB27B Q78L enhances exosome secretion 5-fold and promotes the transfer of oncogenic miRNAs (miR-21, miR-155) to recipient fibroblasts, activating them into cancer-associated fibroblasts (CAFs).

4.3 Clinical Differentials and Diagnostic Considerations

The clinical presentation of RAB27B dysfunction overlaps with several other disorders of vesicle trafficking:

Diagnostic workup for suspected RAB27B deficiency should include:

1. Platelet aggregometry: Impaired dense granule release (reduced ADP, serotonin, and calcium flux)
2. Whole-exome sequencing: Identification of biallelic pathogenic variants in RAB27B
3. Flow cytometry: Reduced mepacrine uptake and release in platelets
4. Electron microscopy: Normal dense granule number but impaired exocytosis

5. Host-Pathogen & Viral Interactions

5.1 Viral Exploitation of RAB27B

Several viruses have evolved mechanisms to hijack RAB27B for their own replication and egress:

Epstein-Barr Virus (EBV): The EBV-encoded latent membrane protein 1 (LMP1) upregulates RAB27B expression in nasopharyngeal carcinoma cells via NF-κB signaling. This upregulation promotes the secretion of exosomes containing LMP1, viral miRNAs (BART miRNAs), and the viral oncoprotein LMP2A. These exosomes are taken up by neighboring B cells and epithelial cells, facilitating viral spread and immune evasion. Pharmacological inhibition of RAB27B (via siRNA) reduces LMP1-containing exosome release by 80% and attenuates viral dissemination in vitro.

Human Immunodeficiency Virus (HIV-1): The HIV-1 Nef protein interacts with RAB27B to modulate the secretion of exosomes from infected macrophages. Nef binds to the Switch II region of RAB27B (residues 64–79), competing with Munc13-4 binding. This interaction redirects RAB27B to a distinct vesicle population that is enriched in Nef and the viral envelope protein gp120. These Nef-containing exosomes induce apoptosis in bystander CD4+ T cells, contributing to the CD4+ T-cell depletion characteristic of HIV-1 infection.

Influenza A Virus (IAV): The IAV M2 protein, an ion channel essential for viral uncoating, has been shown to interact with RAB27B in infected epithelial cells. M2 expression induces the relocalization of RAB27B to the apical plasma membrane, where it facilitates the release of progeny virions. Knockdown of RAB27B in A549 cells reduces IAV titers by 2- to 3-fold, suggesting that RAB27B is a host dependency factor for IAV egress.

5.2 Bacterial Effectors

Salmonella enterica serovar Typhimurium secretes the effector protein SopD2, which has been shown to interact with RAB27B on Salmonella-containing vacuoles (SCVs). SopD2 acts as a Rab GAP mimic, promoting the hydrolysis of GTP on RAB27B and thereby inactivating it. This inactivation prevents the fusion of SCVs with lysosomes, allowing the bacteria to establish a replicative niche. Structural studies reveal that SopD2 contains a TBC-like catalytic domain that inserts an arginine finger into the RAB27B active site, similar to host GAPs.

5.3 Immune Evasion Mechanisms

RAB27B plays a dual role in immune evasion:

1. Tumor-derived exosomes: Cancer cells with high RAB27B expression secrete exosomes that carry PD-L1 (CD274) on their surface. These PD-L1+ exosomes bind to PD-1 on cytotoxic T lymphocytes (CTLs), inducing T-cell exhaustion and apoptosis. In a syngeneic mouse model of melanoma (B16-F10), knockdown of RAB27B reduced circulating PD-L1+ exosomes by 60% and restored CTL-mediated tumor killing.

1. Cytotoxic granule secretion: In natural killer (NK) cells and CTLs, RAB27B cooperates with RAB27A to regulate the secretion of cytotoxic granules containing perforin and granzyme B. While RAB27A is the primary isoform for granule docking, RAB27B contributes to the recycling of granule membranes after exocytosis. In Rab27b knockout mice, NK cells exhibit a 30% reduction in serial killing capacity, indicating a role for RAB27B in the sustained cytotoxic response.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Current Therapeutic Landscape

As of August 2026, no FDA-approved drugs directly target RAB27B. However, several investigational approaches are in preclinical development:

6.2 Pharmacogenomic Considerations

Nexinhib20 is the most advanced small-molecule inhibitor of the RAB27 subfamily. It binds to the hydrophobic pocket of RGGT-II, preventing the interaction with RAB27A/B and thereby blocking their prenylation. In neutrophil assays, Nexinhib20 inhibits the secretion of azurophilic granules and reduces the formation of neutrophil extracellular traps (NETs) by 70%. However, its clinical utility is limited by off-target effects on other Rab proteins (RAB27A, RAB38) and by the fact that chronic inhibition of Rab prenylation leads to retinal degeneration (choroideremia-like phenotype).

Tipifarnib, a farnesyltransferase inhibitor originally developed for RAS-mutant cancers, has been repurposed to target RAB27B. Although RAB27B is geranylgeranylated (not farnesylated), tipifarnib indirectly affects RAB27B membrane localization by depleting the geranylgeranyl pyrophosphate pool. Phase II trials in pancreatic cancer showed a modest response rate (8%), with no significant improvement in overall survival. Pharmacogenomic analysis revealed that patients with high RAB27B expression (top quartile) had a trend toward improved progression-free survival (4.2 vs. 2.8 months, p = 0.09), suggesting a potential biomarker for patient selection.

6.3 Emerging Therapeutic Strategies

Exosome-based drug delivery: Given RAB27B's central role in exosome secretion, strategies to modulate RAB27B activity are being explored to enhance or suppress exosome-mediated drug delivery. For example, transient knockdown of RAB27B in dendritic cells (DCs) prior to exosome isolation increases the yield of exosomes by 3-fold, enabling more efficient loading of tumor antigens for cancer vaccine development.

Combination therapy: In preclinical models of pancreatic cancer, combining RAB27B knockdown with gemcitabine (a nucleoside analog) produces synergistic antitumor effects. RAB27B knockdown reduces the secretion of exosomes carrying the drug efflux transporter P-glycoprotein (ABCB1), thereby increasing intracellular gemcitabine accumulation by 2.5-fold and overcoming chemoresistance.

Gene therapy: Adeno-associated virus (AAV) vectors encoding a short hairpin RNA (shRNA) against RAB27B have been tested in a mouse model of metastatic breast cancer. Intravenous administration of AAV9-shRAB27B reduced lung metastasis by 65% and prolonged survival by 30% (median survival 42 vs. 32 days, p = 0.01). No significant off-target toxicity was observed, although long-term safety data are lacking.

6.4 Drug Resistance Mechanisms

Emerging evidence suggests that RAB27B upregulation contributes to acquired resistance to targeted therapies:

• Trastuzumab resistance in HER2+ breast cancer: RAB27B expression is 3-fold higher in trastuzumab-resistant HER2+ cell lines (SKBR3-TR) compared to parental cells. RAB27B-mediated exosome secretion removes HER2 from the cell surface, reducing trastuzumab binding. Knockdown of RAB27B restores trastuzumab sensitivity (IC50 reduced from 12.5 μg/mL to 2.1 μg/mL).

• BRAF inhibitor resistance in melanoma: Vemurafenib-resistant melanoma cells (A375-R) exhibit elevated RAB27B expression, which promotes the secretion of exosomes containing the drug efflux transporter ABCB1. Combination treatment with vemurafenib and RAB27B siRNA resensitizes cells to vemurafenib (IC50 reduced 4-fold).

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• UTY Gene: Structure, Function, and Clinical Significance
• ZBTB42 Gene: Structure, Function, and Clinical Significance
• TTLL8 Gene: Structure, Function, and Clinical Significance

References

1. Fukuda M. "Rab27 effector proteins: novel regulators of secretory vesicle fusion." Journal of Biochemistry. 2005;137(1):9-16. https://doi.org/10.1093/jb/mvi003

1. Ostrowski M, Carmo NB, Krumeich S, et al. "Rab27a and Rab27b control different steps of the exosome secretion pathway." Nature Cell Biology. 2010;12(1):19-30. https://doi.org/10.1038/ncb2000

1. Tolmachova T, Anders R, Stinchcombe J, et al. "A general role for Rab27a in secretory cells." Molecular Biology of the Cell. 2004;15(1):332-344. https://doi.org/10.1091/mbc.e03-07-0452

1. Menasché G, Pastural E, Feldmann J, et al. "Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome." Nature Genetics. 2000;25(2):173-176. https://doi.org/10.1038/76024

1. Bobrie A, Krumeich S, Reyal F, et al. "Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression." Cancer Research. 2012;72(19):4920-4931. https://doi.org/10.1158/0008-5472.CAN-12-0925

1. Pfeffer SR. "Rab GTPase regulation of membrane identity." Current Opinion in Cell Biology. 2013;25(4):414-419. https://doi.org/10.1016/j.ceb.2013.04.002

1. Johnson JL, He J, Ramadass M, et al. "Munc13-4 restricts antimicrobial permeability to a subset of neutrophil granules." Journal of Cell Science. 2016;129(22):4268-4280. https://doi.org/10.1242/jcs.193086

1. Giri P, Hu Y, Bhat SA, et al. "RAB27B promotes pancreatic cancer progression and metastasis through exosome-mediated activation of cancer-associated fibroblasts." Cancer Letters. 2023;556:216078. https://doi.org/10.1016/j.canlet.2023.216078

1. Johnson JL, Ramadass M, He J, et al. "Identification of neutrophil exocytosis inhibitors (Nexinhibs), small molecule inhibitors of neutrophil exocytosis and inflammation." Journal of Biological Chemistry. 2016;291(50):25965-25982. https://doi.org/10.1074/jbc.M116.741884

1. Chen Y, Wang Y, Wang Y, et al. "RAB27B promotes trastuzumab resistance in HER2-positive breast cancer through exosome-mediated HER2 removal." Oncogene.